Nilotinib Zentiva

Nilotinib, the active ingredient in Nilotinib Zentiva, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia in the chronic phase, targeting the BCR‑ABL protein that drives malignant cell growth. GNH USA supplies Nilotinib Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nilotinib targets the BCR‑ABL tyrosine‑kinase pathway and is used in the management of chronic myeloid leukemia. - Chronic myeloid leukemia (chronic phase): reduces leukemic cell proliferation and improves survival. - Philadelphia‑positive CML after imatinib resistance: provides an alternative targeted therapy. - Maintenance therapy for patients who have achieved a molecular response: helps sustain remission.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools that may require fluid replacement. - Rash: skin irritation or erythema. - Elevated liver enzymes: mild transaminase increase. - Fatigue: generalized tiredness. - Headache: occasional throbbing pain.

Serious or Rare Side Effects: - Cardiovascular events: myocardial infarction or arterial occlusion. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe hepatic dysfunction: marked elevation of liver enzymes or jaundice. - QT interval prolongation: risk of arrhythmia requiring ECG monitoring.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor relevant parameters. - Cardiac assessment: baseline ECG and periodic monitoring for QT prolongation. - Liver function: check transaminases before start and during treatment. - Pancreatic enzymes: monitor amylase and lipase if abdominal symptoms arise. - Drug interactions: review concomitant medications that affect CYP3A4. - Pregnancy and lactation: avoid use unless benefits outweigh risks; discuss with specialist. Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Nilotinib interacts with several agents that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce nilotinib exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): significantly increase nilotinib levels and risk of QT prolongation. - Antacids containing aluminum or magnesium: may decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may modestly reduce absorption; separate dosing by at least 2 hours. - Statins metabolized by CYP3A4 (e.g., simvastatin): may increase statin exposure; consider dose adjustment. - Anticoagulants (warfarin): monitor INR more frequently due to potential interaction.